AI Platforms and Tools November 17, 2025

Elevating Drug Safety with AI: Smart Launch’s DILI Prediction Alternative to Libra

By Maggie

alt=”background pattern for drug safety analytics” title=”Background Pattern – Drug Safety Analytics”

Meta Description: Discover how Smart Launch’s AI-driven platform outperforms traditional DILI tools with unified drug safety analytics, real-time insights, and launch optimisation.

Drug-induced liver injury (DILI) remains a leading cause of late-stage failures. The stakes? Billions in wasted R&D spend. The solution? Early, accurate drug safety analytics powered by AI. Enter two contenders in this space:

Libra™ by Certara
Smart Launch by ConformanceX

Let’s compare. Spoiler alert: one platform goes beyond isolated prediction and ties safety insights directly to launch success.

The Challenge: Predicting DILI Before It’s Too Late

Every new compound carries risk. Traditional safety assessments rely on:

Costly in vitro assays
Time-consuming animal studies
Late clinical signals

By the time you spot a liver risk, you’ve spent millions. Worse—your project timeline slips. You need drug safety analytics that forecast hazards early, feed into R&D decisions, and guide your launch strategy in real time.

Libra™ at a Glance

Certara’s Libra™ is an AI-powered tool for DILI prediction, integrated within ToxStudio®. Key strengths:

QSAR Modelling
Predicts DILI hazards even before you synthesise compounds.
Bayesian Predictive Model
Merges physicochemical and in vitro data to flag risk compounds early.
User-Friendly Interface
Designed for non-modellers.
Automated Reports
Generates charts and summaries for project teams and senior management.

Plus, Libra sits within Certara’s Non-Animal Navigator™, supporting new approach methodologies. Impressive. But is it enough?

Limitations of a Single-Focus Tool

Libra excels at spotting DILI signals. Yet:

It’s siloed from market intelligence.
It doesn’t tie liver-safety risk to launch strategies.
Real-time adjustments? Not its core strength.
Competitive intelligence? Not included.

In other words: you still juggle separate platforms for safety analytics and launch planning.

Introducing Smart Launch: Unified Drug Safety Analytics and Launch Optimisation

What if DILI prediction lived alongside market insights, launch timelines, and competitive data? That’s Smart Launch’s promise. Here’s why it matters:

Integrated AI Insights
Real-time drug safety analytics feed directly into your launch dashboard.
Comprehensive Predictive Analytics
From DILI to market uptake—one platform, all risk signals.
Competitive Intelligence
Tailored reports show how rivals position similar compounds.
Real-Time Monitoring
Spot safety or market shifts as they happen. Pivot in hours, not weeks.
Scalable Across Regions
Localise insights for Europe, North America, or emerging markets.

No more fragmentation. Just one source of truth for both safety and launch teams.

Side-by-Side: Smart Launch vs. Libra™

Scope
• Libra: Focus on DILI prediction
• Smart Launch: DILI + broader safety risks + launch strategy

Data Integration
• Libra: Physicochemical + in vitro
• Smart Launch: Clinical, market, competitive, real-world

Real-Time Insights
• Libra: Batch analyses with scheduled updates
• Smart Launch: Continuous streaming updates

Competitive Intelligence
• Libra: Not included
• Smart Launch: Built-in dashboards

Report Automation
• Libra: Static reports for safety teams
• Smart Launch: Dynamic reports for cross-functional teams

Scalability
• Libra: Within ToxStudio ecosystem
• Smart Launch: Modular for multiple regions and therapeutic areas

How Smart Launch Bridges the Gaps

You’ve seen the comparison. Now, here’s how Smart Launch solves those pain points:

Unified Platform
Safety, market, and launch data converge in one dashboard. No more context switching.
AI-Driven Risk Scores
DILI, cardiac safety, off-target risks—scored and trended side by side.
Actionable Alerts
Get notified when a compound’s risk profile shifts or when a competitor files a new patent.
Strategic Playbooks
Pre-built launch templates ensure you hit critical milestones on time.
Continuous Improvement
Regular updates incorporate the latest modelling techniques and user feedback.

Practical Tips: Maximising Your Drug Safety Analytics

Ready to supercharge your launch with smarter safety data? Here are three steps:

Centralise Your Data
Bring R&D, clinical, and market datasets into Smart Launch.
• Start with your safety assay results.
• Add protocol and competitive intelligence feeds.
Define Your Risk Thresholds
Set custom alert levels for DILI probabilities and market share declines.
• Example: Flag compounds with >30% DILI risk for immediate review.
• Example: Alert marketing when a competitor’s phase-III results drop.
Leverage AI Insights for Rapid Pivots
When an alert fires, use Smart Launch’s dashboards to explore root causes.
• Drill into risk factors.
• Revise your launch timeline.
• Adjust your marketing positioning.

The result? A lean, data-driven workflow that reduces surprises and maximises success.

Why SMEs in Europe Are Choosing Smart Launch

Small to medium enterprises often lack large safety teams or in-house data science. Smart Launch levels the playing field:

No heavy tech overhead.
Easy adoption, rapid onboarding.
Pre-configured workflows for Europe’s regulatory environment.
Transparent pricing for growing businesses.

Whether you have ten compounds or a blockbuster pipeline, you gain enterprise-grade drug safety analytics without breaking the bank.

The Bottom Line

Libra™ brought a fresh perspective to DILI prediction. But when you need more than a safety silo—when you want to connect drug safety analytics with real-world launch success—Smart Launch shines.